» Articles » PMID: 34959134

Accuracy and Ease-of-use of Seven Point-of-care SARS-CoV-2 Antigen-detecting Tests: A Multi-centre Clinical Evaluation

Abstract

Background: Antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are important diagnostic tools. We assessed clinical performance and ease-of-use of seven Ag-RDTs in a prospective, manufacturer-independent, multi-centre cross-sectional diagnostic accuracy study to inform global decision makers.

Methods: Unvaccinated participants suspected of a first SARS-CoV-2 infection were recruited at six sites (Germany, Brazil). Ag-RDTs were evaluated sequentially, with collection of paired swabs for routine reverse transcription polymerase chain reaction (RT-PCR) testing and Ag-RDT testing. Performance was compared to RT-PCR overall and in sub-group analyses (viral load, symptoms, symptoms duration). To understandusability a System Usability Scale (SUS) questionnaire and ease-of-use (EoU) assessment were performed.

Findings: 7471 participants were included in the analysis. Sensitivities across Ag-RDTs ranged from 70·4%-90·1%, specificities were above 97·2% for all Ag-RDTs but one (93·1%).Ag-RDTs, Mologic, Bionote, Standard Q, showed diagnostic accuracy in line with WHO targets (> 80% sensitivity, > 97% specificity). All tests showed high sensitivity in the first three days after symptom onset (≥87·1%) and in individuals with viral loads≥ 6 logSARS-CoV2 RNA copies/mL (≥ 88·7%). Usability varied, with Rapigen, Bionote and Standard Q reaching very good scores; 90, 88 and 84/100, respectively.

Interpretation: Variability in test performance is partially explained by variable viral loads in population evaluated over the course of the pandemic. All Ag-RDTs reach high sensitivity early in the disease and in individuals with high viral loads, supporting their role in identifying transmission relevant infections. For easy-to-use tests, performance shown will likely be maintained in routine implementation.

Funding: Ministry of Science, Research and Arts, State of Baden-Wuerttemberg, Germany, internal funds from Heidelberg University Hospital, University Hospital Charité - Universitätsmedizin Berlin, UK Department of International Development, WHO, Unitaid.

Citing Articles

Clinical accuracy of instrument-based SARS-CoV-2 antigen diagnostic tests: a systematic review and meta-analysis.

Manten K, Katzenschlager S, Brummer L, Schmitz S, Gaeddert M, Erdmann C Virol J. 2024; 21(1):99.

PMID: 38685117 PMC: 11059670. DOI: 10.1186/s12985-024-02371-5.


Point of Care Tests: Changing Paradigms in the Diagnosis of SARS-CoV-2.

Sharma A, Chourasia E, Goswami S Heart Views. 2024; 24(4):194-200.

PMID: 38188704 PMC: 10766159. DOI: 10.4103/heartviews.heartviews_31_23.


Clinical Evaluation and Comparison of Two Microfluidic Antigenic Assays for Detection of SARS-CoV-2 Virus.

Bottino P, Pizzo V, Castaldo S, Scomparin E, Bara C, Cerrato M Microorganisms. 2023; 11(11).

PMID: 38004721 PMC: 10673207. DOI: 10.3390/microorganisms11112709.


Clinical performance of SARS-CoV-2 antigen-detection rapid diagnostic test using SERS-based lateral flow immunoassay.

Yoon S, Lim Y, Kweon O, Kim T, Lee M Heliyon. 2023; 9(9):e19492.

PMID: 37809408 PMC: 10558587. DOI: 10.1016/j.heliyon.2023.e19492.


[Diagnostic performance of two antigen-tests compared to one PCR-Test to detect SARS-CoV-2 in an emergency department and emergency service].

Kinne V, Ehrenberg S, Baier M, Lang S, Lewejohann J, Kipp F Anaesthesiologie. 2023; 72(11):791-798.

PMID: 37792046 PMC: 10615947. DOI: 10.1007/s00101-023-01343-8.


References
1.
Cubas-Atienzar A, Kontogianni K, Edwards T, Wooding D, Buist K, Thompson C . Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. Sci Rep. 2021; 11(1):18313. PMC: 8443584. DOI: 10.1038/s41598-021-97489-9. View

2.
Boehme C, Hannay E, Sampath R . SARS-CoV-2 testing for public health use: core principles and considerations for defined use settings. Lancet Glob Health. 2021; 9(3):e247-e249. PMC: 7906635. DOI: 10.1016/S2214-109X(21)00006-1. View

3.
Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H . Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg Infect Dis. 2020; 26(8):1834-1838. PMC: 7392422. DOI: 10.3201/eid2608.201097. View

4.
Prince-Guerra J, Almendares O, Nolen L, Gunn J, Dale A, Buono S . Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(3):100-105. PMC: 7821766. DOI: 10.15585/mmwr.mm7003e3. View

5.
Corman V, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3). PMC: 6988269. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045. View